Syros Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SYRS Nasdaq 8731 https://syros.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Syros Pharmaceuticals Inc

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 1st, 2023 8:30 pm
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting - May 25th, 2023 9:05 pm
One Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \ - May 25th, 2023 12:44 pm
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript - May 13th, 2023 2:15 pm
Q1 2023 Syros Pharmaceuticals Inc Earnings Call - May 11th, 2023 2:08 am
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates - May 10th, 2023 12:45 pm
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update - May 10th, 2023 11:30 am
Syros to Present at JMP Securities 2023 Life Sciences Conference - May 9th, 2023 11:00 am
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? - May 8th, 2023 12:40 am
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 - May 3rd, 2023 11:30 am
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript - Mar 6th, 2023 2:48 pm
Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag - Mar 4th, 2023 12:08 pm
Q4 2022 Syros Pharmaceuticals Inc Earnings Call - Mar 3rd, 2023 3:02 am
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates - Mar 2nd, 2023 2:35 pm
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update - Mar 2nd, 2023 12:30 pm
Syros to Participate in Upcoming Investor Conferences in March - Feb 28th, 2023 12:30 pm
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 - Feb 23rd, 2023 12:30 pm
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? - Feb 1st, 2023 2:43 pm
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome - Jan 26th, 2023 12:00 pm
Syros Announces Clinical Updates and 2023 Strategic Priorities - Jan 9th, 2023 12:00 pm